<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342585</url>
  </required_header>
  <id_info>
    <org_study_id>JEP-2020-065</org_study_id>
    <secondary_id>DIP-2019-028</secondary_id>
    <nct_id>NCT04342585</nct_id>
  </id_info>
  <brief_title>Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical Length</brief_title>
  <official_title>Randomised Controlled Trial Comparing Vaginal Pessary and Progestogen as an Intervention in Twin Pregnancy With Short Cervical Length to Prevent Spontaneous Preterm Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial comparing vaginal progestogen and vaginal pessary as an
      intervention for twin pregnancies with short cervical length.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial to compare women with twin pregnancies and diagnosed
      with asymptomatic short cervical length. Two types of interventions will be compared i.e
      vaginal progestogen and vaginal pessary.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All women with twin pregnancies will be screened for suitability via measurement of the cervical length at 20 to 24 weeks gestation. Those with a cervical length of 30mm or less will be recruited into the study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous preterm birth</measure>
    <time_frame>Through study completion up to 37 weeks</time_frame>
    <description>Mean gestational age at delivery in weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal age</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean maternal age in years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Race</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Percentage of each race recruited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal body mass index</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean maternal body mass index in kg/m2 before pregnancy or in the first trimester</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parity</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean number of parity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of twin pregnancy</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Chorionicity of twin pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of conception</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Method of conception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at recruitment</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean gestational age at recruitment in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at commencement of treatment</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean gestational age at commencement of treatment in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical length before commencement of treatment</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean cervical length before commencement of treatment in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal infection</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Percentage of participants with vaginal infection prior to commencement of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous miscarriages</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Percentage of participants with previous first and second trimester miscarriages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-existing medical disorders</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Percentage of participants with pre-existing medical disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous spontaneous preterm birth</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Percentage of participants with previous spontaneous preterm birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antenatal complications</measure>
    <time_frame>Through study completion up to 37 weeks</time_frame>
    <description>Percentage of participants with antenatal complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal complications</measure>
    <time_frame>Through study completion up to 37 weeks</time_frame>
    <description>Percentage of participants with fetal complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>Through study completion up to 37 weeks</time_frame>
    <description>Percentage of participants who delivered vaginally or via caesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrapartum complications</measure>
    <time_frame>Throughout labour up to delivery of the neonate</time_frame>
    <description>Percentage of participants with intrapartum complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum complications</measure>
    <time_frame>Through delivery of neonate up to 42 days after delivery</time_frame>
    <description>Percentage of participants with postpartum complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>Through delivery of neonate up to 42 days after delivery</time_frame>
    <description>Mean total blood loss in ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Immediately after birth of neonate</time_frame>
    <description>Mean birth weight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>Immediately after birth of neonate</time_frame>
    <description>Mean Apgar score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry assessment of neonates</measure>
    <time_frame>Immediately after birth of neonate</time_frame>
    <description>Mean length and head circumference of neonates at birth in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admission</measure>
    <time_frame>Immediately after birth of neonate up to discharge (approximately 30 days)</time_frame>
    <description>Percentage of neonates required Neonatal intensive care unit admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in neonatal intensive care unit</measure>
    <time_frame>Through neonatal intensive care unit stay up to discharge (approximately 30 days)</time_frame>
    <description>Mean duration in neonatal intensive care unit in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal complications</measure>
    <time_frame>Immediately after birth up to 30 days</time_frame>
    <description>Percentage of neonates with complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Vaginal progestogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg of vaginal progestogen will be inserted before bedtime every day from time of recruitment until 34 weeks gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal pessary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal pessary with an internal diameter size of 32 or 35 mm will be inserted at the time of recruitment and kept until 34 weeks gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronised vaginal progesterone</intervention_name>
    <description>A diary will be given to participants to ensure compliance.</description>
    <arm_group_label>Vaginal progestogen</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vaginal pessary</intervention_name>
    <description>The internal diameter size will be decided based on the clinical assessment of the cervix.</description>
    <arm_group_label>Vaginal pessary</arm_group_label>
    <other_name>Arabin pessary</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all twin pregnancies

          -  cervical length less than 30mm

        Exclusion Criteria:

          -  Twin to twin transfusion syndrome

          -  Stillbirth

          -  congenital anomaly in one of the fetuses

          -  previous cervical trauma or surgery

          -  cervical cerclage in current pregnancy

          -  premature labour with or without rupture of membranes

          -  severe vaginal discharge

          -  acute vaginitis or cervicitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UKM Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Rahana Abd Rahman</last_name>
      <email>drrahana@ppukm.ukm.edu.my</email>
    </contact>
    <contact_backup>
      <last_name>Shuhaila Ahmad</last_name>
      <email>shuhaila@ppukm.ukm.edu.my</email>
    </contact_backup>
    <investigator>
      <last_name>Nurul Ilani Abdul Latif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Rahana Abd Rahman</investigator_full_name>
    <investigator_title>Co-primary investigator</investigator_title>
  </responsible_party>
  <keyword>twin</keyword>
  <keyword>vaginal pessary</keyword>
  <keyword>vaginal progestogen</keyword>
  <keyword>short cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

